Three ongoing intraperitoneal chemotherapy trials in ovarian cancer
- PMID: 22523620
- PMCID: PMC3325351
- DOI: 10.3802/jgo.2012.23.2.75
Three ongoing intraperitoneal chemotherapy trials in ovarian cancer
Conflict of interest statement
No potential conflict of interests relevant to this article was reported.
Comment on
- J Gynecol Oncol. 23:91.
References
-
- Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1–20. - PubMed
-
- Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955. - PubMed
-
- Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–1007. - PubMed
-
- Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43. - PubMed
-
- National Cancer Institute. Bethesda, MD: National Cancer Institute; 2006. [cited 2012 Mar 10]. NCI clinical announcement: intraperitoneal chemotherapy for ovarian cancer [Internet] Available from: http://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf.
